Clinical Trials Blog

May 2025 clinical trial highlights

by Pulmonary Fibrosis Foundation
May 20, 2025
Clinical trial participants are essential in the quest for new treatments and a cure for pulmonary fibrosis (PF).

In the May 2025 clinical trial highlights, we'll showcase just a few of the many trials that are enrolling volunteers. To view more available trials for various forms of interstitial lung disease (ILD), please visit the 🔍 PFF Clinical Trial Finder.

Keep reading to learn more about this month’s featured trials ↓

Seeking participants with IPF

ALOFT-IPF
Study ID: NCT06003426
Trial Phase: Phase 3
Intervention: Oral drug
Sponsor: Bristol-Myers Squibb

Study Contact: Clinical.Trials@bms.com, 855.907.3286

Seeking participants with IPF

DWN12088 in IPF
Study ID: NCT05389215
Trial Phase: Phase 2
Intervention: Oral drug
Sponsor: Daewoong Pharmaceutical Co. LTD.

Study Contact: YeaRa Kwak yeara.kwak@daewoong.co.kr; +82.2.550.8010

Seeking participants with SSc-ILD

Efzofitimod in SSc-ILD
Study ID: NCT05892614
Trial Phase: Phase 2
Intervention: Intravenous injection
Sponsor: aTyr Pharma, Inc.
Study Contact: SScILD@cssienroll.com; 877.689.4494

Seeking participants with fibrotic ILD

Pulmonary Rehabilitation and Health Coaching in Fibrotic Interstitial Lung Disease
Study ID: NCT06751069
Intervention: Home-based pulmonary rehabilitation
Sponsor: Mayo Clinic
Study Contact: Johanna Hoult, MS hoult.johanna@mayo.edu; 507.293.1989

Putting a Face to the Science: Living with IPF

When Mario started feeling out of breath during a trip to South America, he thought his breathing difficulties were caused by wearing a mask in the heat. When he returned home, he went to see his doctor just to make sure.

Hearing the diagnosis of idiopathic pulmonary fibrosis (IPF) was devastating. He researched the disease on the internet but only found bad news. 

Then he discovered the support and resources provided by the PFF, and his whole outlook changed. He decided he wasn’t going to let IPF stop him from enjoying life. He is determined to travel and spend time with family and friends while he savors every moment. Today, Mario raises awareness of IPF and campaigns for a cure as a PFF Ambassador.

Participating in IPF research helps the scientific discovery process for people like Mario. To learn more about IPF, visit the IPF webpage.

Keep reading for the latest research updates and resources ↓

RSVP for the PFF’s Clinical Trial Webinar Series in June

On Wednesday, June 4, 2025, from noon to 1 p.m. CT, join the PFF and industry representatives for the second webinar in the PFF Clinical Trial Innovation (CTI) Webinar Series. Speakers will talk about the following trials underway to help find new treatments for PF and ILD.
Trial SponsorTrial TitleSpeaker
Vicore Pharma ABA Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis (ASPIRE)James Nolin, PhD; Senior Clinical Science Liaison at Vicore Pharma AB
Boehringer IngelheimA Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary FibrosisThomas Porter, MBA, MPH; Director, Clinical Development Lead at Boehringer Ingelheim
Pulmonary Fibrosis FoundationPFF Community RegistryJessica Shore, PhD, RN; Senior Vice President, Clinical Affairs and Quality at PFF